Development of a high-affinity PD-L1 decoy protein as a therapeutic molecule.
Programmed cell death protein-1 (PD-1) and its ligand (PD-L1) are immune checkpoint proteins that inform the response of cytotoxic T lymphocytes (CTLs) that have recognized tumor cell antigen presentation on major histocompatibility complexes (MHCs) via T cell receptors (TCRs).
Successful signaling between PD-1 and PD-L1 suppresses the anti-tumor immune response of CTLs, allowing tumor cells to proliferate. Blockade of PD-1/PD-L1 signaling is therefore a promising cancer treatment strategy.
Our goal is to engineer an oligomeric decoy with enhanced binding affinity (avidity) to PD-L1 such that it can effectively result in blockade and confer a therapeutic benefit.
If you are interested in PD-L1 Decoy project, please feel free to contact us for further discussion!